{"id":62527,"date":"2026-01-22T07:06:04","date_gmt":"2026-01-22T06:06:04","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/"},"modified":"2026-01-22T07:06:04","modified_gmt":"2026-01-22T06:06:04","slug":"imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/","title":{"rendered":"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\nAt IMCAS 2026, Galderma will present findings supporting Sculptra\u2019s<sup>\u00ae<\/sup> regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas<sup>1-7<\/sup><\/li>\n<li>\nMultiple studies will reinforce the safety and efficacy of Galderma\u2019s hyaluronic acid (HA) treatments range, including post-marketing data on Restylane<sup>\u00ae<\/sup> Shaype\u2122 in shaping the chin, Restylane Lyft\u2122 in improving jawline definition, Restylane Skinboosters\u2122 in smoothing fine lines and wrinkles in the d\u00e9colletage and Restylane Volyme\u2122 in correcting hollowing of the temples<sup>8-11<\/sup><\/li>\n<li>\nNew data on the innovative neuromodulator Relfydess\u2122 (RelabotulinumtoxinA) will reinforce its rapid onset as early as Day 1 and sustained efficacy through six months for frown lines and crow\u2019s feet<sup>12<\/sup><\/li>\n<li>\nAs a leader in injectable aesthetic innovation, Galderma will showcase its superior science and educational capabilities at the congress<\/li>\n<\/ul>\n<p>ZUG, Switzerland&#8211;(BUSINESS WIRE)&#8211;Galderma (SIX: GALD) will present ten posters with the latest updates from across its broad aesthetic portfolio spanning regenerative biostimulation, HA and neuromodulator treatments at the International Master Course on Aging Science (IMCAS) 2026 World Congress in Paris, France, from January 29-31, 2026. The company will also showcase its leadership in community education through a number of events including two symposia, a live anatomy workshop, multiple masterclasses and meet-the-expert sessions, and a booth that will delve into the science behind its innovations.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><br \/><a href=\"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/5\/GALDERMA_LOGO_BLACK_RGB.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/21\/GALDERMA_LOGO_BLACK_RGB.jpg\"><\/a><\/p>\n<table cellspacing=\"0\" class=\"bwblockalignl bwtablemarginb\">\n<tr>\n<td class=\"bwpadl0 bwrowaltcolor0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin bwalignc\">\n\u201cWith ten posters spanning all key aesthetic treatment modalities and areas across the face and body, our data at IMCAS truly showcases the breadth and versatility of our injectable aesthetics portfolio and how we continue to drive innovation with our trusted products. In tandem with our first-class Galderma Aesthetic Injector Network (GAIN) educational activities, conducted in partnership with renowned experts, we are equipping practitioners with all the tools they need to take a personalized and holistic approach to treatment.\u201d<\/p>\n<p><b>BILL ANDRIOPOULOS, PH.D.<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>HEAD OF GLOBAL MEDICAL AFFAIRS<\/b><\/p>\n<p class=\"bwalignc bwcellpmargin\">\n<b>GALDERMA<\/b><\/p>\n<\/td>\n<td class=\"bwvertalignt bwpadl0 bwrowaltcolor0\" colspan=\"1\" rowspan=\"1\">\n<p class=\"bwcellpmargin\">\n\u00a0<\/p>\n<\/td>\n<\/tr>\n<\/table>\n<p>\n<b>Biostimulation: Sculptra\u2019s innovative approach to regenerative aesthetics for the face and body backed by experts<br \/>\n<br \/><\/b>In response to patients increasingly seeking harmony between facial and body aesthetics, Galderma <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Fsculptra-mdr-certification-body&amp;esheet=54401298&amp;newsitemid=20260121547346&amp;lan=en-US&amp;anchor=recently&amp;index=1&amp;md5=21bfdd5798b05466461d57cb39670c02\" rel=\"nofollow\" shape=\"rect\">recently<\/a> announced the EU MDR certification of Sculptra, the first proven regenerative biostimulator, expanding its current clinical use to the body.<sup>3<\/sup> At IMCAS, guidance developed by 13 international experts on Sculptra\u2019s four MDR-approved indications \u2013 the gluteal area, posterior thighs, d\u00e9colletage, and upper arms \u2013 will be presented.<sup>1<\/sup> The experts concluded that Sculptra\u2019s benefits can be complemented with Restylane Skinboosters in the d\u00e9colletage for comprehensive body rejuvenation, and recommended injection volumes for Sculptra to be used in the posterior thighs, upper arms and gluteal area to improve aesthetic appearance, including skin firmness and reduced appearance of cellulite.<sup>1<\/sup><\/p>\n<p>\nResults from an expert review of data on Sculptra will also be presented, providing additional evidence of its regenerative properties.<sup>2<\/sup> This includes fibroblast activation leading to stimulation of collagen, elastin and other proteins involved in extracellular matrix regeneration and adipogenesis (the formation of healthy fat cells).<sup>2<\/sup> This clinically presents as long-term improvements such as increased volume, elasticity, and skin thickness.<sup>2<\/sup><\/p>\n<p>\nA final poster will examine the ease of Sculptra\u2019s reconstitution process compared with two other poly-L-lactic acid biostimulators, finding that healthcare professionals had a strong preference for Sculptra\u2019s reconstitution process and positively rated its speed of administration from preparation to injection.<sup>13<\/sup><\/p>\n<p>\n<b>HA treatments: The Restylane range demonstrates its versatility in meeting diverse patient needs<br \/>\n<br \/><\/b>Data from across Galderma\u2019s portfolio of Restylane HA treatments will be presented supporting its versatile use on the face and d\u00e9colletage, with a range of gel formulations to meet personalized needs from providing structural support to smoothing lines and wrinkles:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\nThe ARTIST post-marketing study found that Restylane Shaype, powered by new NASHA HD\u2122 technology, is a safe and effective treatment for shaping the chin with natural-looking results, alone or in combination with Restylane Defyne\u2122 and Restylane Lyft to provide lift, shape, and definition for diverse aesthetic needs.<sup>8<\/sup> The poster also supports that Restylane Shaype has the highest G-prime (a measure of firmness) compared with other HA treatments produced with different manufacturing technologies, allowing for greater correction with lower injection volumes.<sup>8<\/sup><\/li>\n<li>\nA study of Restylane Lyft for jawline definition showed it was effective and safe, and resulted in high subject satisfaction and aesthetic improvement through 12 months.<sup>9<\/sup><\/li>\n<li>\nA study evaluating the effectiveness and safety of Restylane Skinboosters for correction of moderate-to-severe wrinkles in the d\u00e9colletage found that it was well tolerated and highly efficacious with a significant improvement through Week 32 and high patient satisfaction.<sup>10<\/sup><\/li>\n<li>\nA study of Restylane Volyme showed that it was safe and effective for correction of temple hollowing, with high and sustained results through Month 18 and high patient satisfaction.<sup>11<\/sup><\/li>\n<\/ul>\n<p>\n<b>Neuromodulation: Supporting Relfydess\u2019 next-generation performance<br \/>\n<br \/><\/b>Results will be presented from an analysis of wrinkle morphology and dynamic skin strain in the RELAX and EXPRESSION trials investigating Relfydess \u2013 the first and only ready-to-use liquid neuromodulator created with PEARL<sup>TM<\/sup> Technology.<sup>12,14<\/sup> Results reinforce its onset of action as early as Day 1 in patients with moderate-to-severe frown lines and crow\u2019s feet, with sustained improvements for six months.<sup>12<\/sup> Expert-led consensus recommendations will also be shared addressing important unmet needs in real-world clinical practice and providing clear guidance for the practical use of Relfydess, helping healthcare professionals select the optimal treatment protocol for their patients.<sup>15<\/sup><\/p>\n<p>\n<b>Spearheading community education and awareness around unmet patient needs<br \/>\n<br \/><\/b>Galderma will also present findings from a global survey of over 4,300 women across five continents linking menopause to several skin changes, including wrinkles, loss of firmness, dryness and dull skin, and the potential role of aesthetic treatments to address them.<sup>16,17<\/sup> As part of its response to this, Galderma will host a symposium titled \u2018Menopause in the Mirror: Challenges, Science and Aesthetic Solutions\u2019 on Friday, January 30 at 10:30 AM \u2013 12:30 PM CET in Grand Amphi &#8211; Level 1.<\/p>\n<p>\nA second symposium, titled \u2018Exploring Breakthroughs in Injectable Regeneration for the Face, Body, and Skin Health\u2019 will delve into the growing demand for holistic regenerative aesthetic solutions and take place on Thursday January 29 at 1:30 \u2013 2:30 PM CET in Room 251, Level 2.<\/p>\n<p>\nMore information about Galderma\u2019s activities at IMCAS 2026 can be found <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fnews%2Fimcas-2026-galdermas-scientific-presentations&amp;esheet=54401298&amp;newsitemid=20260121547346&amp;lan=en-US&amp;anchor=here&amp;index=2&amp;md5=f06c33d6df3214ba32407aaf98d17cbd\" rel=\"nofollow\" shape=\"rect\">here<\/a>.<\/p>\n<p>\n<b>About Sculptra<br \/>\n<br \/><\/b>Sculptra is the first proven regenerative biostimulator, with a unique poly-L-lactic acid (PLLA-SCA\u2122) formulation, to provide progressive and sustained regenerative effect across all three skin layers.<sup>3,18-24<\/sup> Sculptra reverses aging processes in the skin, including degradation of the extracellular matrix, which results in volume loss, laxity, and the appearance of wrinkles.<sup>3,18,19,25-27 <\/sup>Sculptra progressively rebuilds the skin\u2019s structural foundation by encouraging the remodeling of components of the extracellular matrix, such as elastin and collagen, helping to gradually restore volume, firmness, radiance and skin quality, and the look of fullness to wrinkles and folds over time.<sup>3-7,18,19,28<\/sup> Sculptra has been shown to provide visible improvements as early as one month after treatment, with results lasting up to two years.<sup>3,6,23,28,29<\/sup><\/p>\n<p>\n<b>About the Restylane portfolio<br \/>\n<br \/><\/b>Restylane HA treatments are designed differently to go beyond volumizing for natural-looking results.<sup>30-33<\/sup> Our HA is minimally modified and our innovative manufacturing process preserves its biocompatibility while creating individual products designed for a specific purpose.<sup>34-37 <\/sup>Powered by NASHA<sup>\u00ae<\/sup>, NASHA HD, OBT\u2122 and SB-NASHA\u2122 technologies, Restylane offers gels with the highest firmness to the highest flexibility, enabling personalized treatments that deliver structural support, natural-looking results, and a healthy glow.<sup>38-41<\/sup> Trusted for almost three decades, our HA gels work in sync with your skin for 100% natural-looking results.<sup>30,42,43<\/sup><\/p>\n<p>\n<b>About Relfydess (RelabotulinumtoxinA)<br \/>\n<br \/><\/b>Pioneered by Galderma, Relfydess is the first and only ready-to-use liquid neuromodulator created with PEARL Technology that is designed to preserve molecule integrity.<sup>14 <\/sup>PEARL Technology is designed to deliver a highly active, innovative, complex-free molecule, with up to 39% of patients seeing effects from day one and up to 75% of patients maintaining improvements for six months.<sup>14,44,45<\/sup> Relfydess is optimized for simple volumetric dosing, without reconstitution, to increase ease-of-use and help ensure consistent dose\/volume every time.<sup>46,47<\/sup> It was entirely created and manufactured by Galderma to expand its neuromodulator portfolio as part of the broadest Injectable Aesthetics portfolio on the market. Relfydess received a marketing authorization in several markets. RelabotulinumtoxinA is an investigational drug product in the U.S. Authorization conditions may vary internationally.<\/p>\n<p>\n<b>About Galderma<br \/>\n<br \/><\/b>Galderma (SIX: GALD) is the pure-play dermatology category leader, present in approximately 90 countries. We deliver an innovative, science-based portfolio of premium flagship brands and services that span the full spectrum of the fast-growing dermatology market through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Since our foundation in 1981, we have dedicated our focus and passion to the human body\u2019s largest organ \u2013 the skin \u2013 meeting individual consumer and patient needs with superior outcomes in partnership with healthcare professionals. Because we understand that the skin we are in shapes our lives, we are advancing dermatology for every skin story. For more information: <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.galderma.com&amp;esheet=54401298&amp;newsitemid=20260121547346&amp;lan=en-US&amp;anchor=www.galderma.com&amp;index=3&amp;md5=7d124fbf94b44a7dd0e03eb3338ebbad\" rel=\"nofollow\" shape=\"rect\">www.galderma.com<\/a>.<\/p>\n<p>\n<b>References<\/b><\/p>\n<ol class=\"bwlistdecimal\">\n<li>\nHaddad A, et al. International consensus: Sculptra<sup>\u00ae<\/sup>\/Restylane<sup>\u00ae<\/sup> Skinboosters\u2122 for non-facial rejuvenation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nFabi SG, et al. Regenerative aesthetic effects of poly L-lactic acid treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nSculptra<sup>\u00ae<\/sup>. EU Instructions for Use. 2025. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.galderma.com%2Fsites%2Fdefault%2Ffiles%2F2025-12%2FIFU_Sculptra_MDR.pdf&amp;esheet=54401298&amp;newsitemid=20260121547346&amp;lan=en-US&amp;anchor=online&amp;index=4&amp;md5=aae897f855c1ee2e8a88171ea49f392e\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed January 2026.<\/li>\n<li>\nGalderma. Data on File. MA-57540.<\/li>\n<li>\nNikolis A, et al. A Prospective, Multicenter Trial on the Efficacy and Safety of Poly-L-Lactic Acid for the Treatment of Contour Deformities of the Buttock Regions. <i>J Drugs Dermatol.<\/i> 2022;21(3):295\u2013303. doi: 10.36849\/JDD.5924.<\/li>\n<li>\nBeleznay K, et al. Safety and Effectiveness of Poly-L-lactic acid (PLLA-SCA) for the Improvement in Appearance of Cellulite \u2013 A Pilot Study. Poster presented at the IMCAS World Congress; February 1-3, 2024; Paris, France.<\/li>\n<li>\nMazzuco R, et al. Clinical and Histological comparative outcomes after injections of Poly-L-Lactic Acid and Calcium Hydroxyapatite in arms \u2013 a split side study. <i>J Cosmet Dermatol<\/i>. 2022;21(12):6727\u20136733. doi: 10.1111\/jocd.15356. Epub 2022 Sep 20.<\/li>\n<li>\nNikolis A, et al. A new NASHA-HD, high G\u2019 hyaluronic acid (HA) injectable evaluated for chin treatment in combination with lower face and mid-face HA filler treatment. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nRivers J, et al. Effectiveness and safety of Restylane<sup>\u00ae<\/sup> Lyft\u2122 Lidocaine for jaw-line definition: A 12-month randomized controlled study. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nMoradi A, et al. Effectiveness and safety of a hyaluronic acid skin quality injectable for the correction of wrinkles in the d\u00e9colletage area. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nNestor M. Safety and effectiveness of an OBT\u2122 hyaluronic acid filler for temple hollowing treatment: a randomized, controlled, clinical investigation. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nMoradi A, et al. Objective image analysis of wrinkle morphology and dynamic skin strain in GLs and LCLs treated with relaBoNT-A in the RELAX and EXPRESSION trials. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nNikolis A, et al. Preferences and experiences across biostimulatory poly-L-lactic acid\u2019s reconstitution processes and injection criteria (PREP study). Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nShridharani SM, et al. Efficacy and safety of RelabotulinumtoxinA, a new ready-to-use liquid formulation botulinum toxin: Results from the READY-1 double-blind, randomized, placebo-controlled phase 3 trial in glabellar lines. <i>Aesthet Surg J.<\/i> 2024;44(12):1330-1340. doi: 10.1093\/asj\/sjae131.<\/li>\n<li>\nAscher B, et al. Consensus Recommendations on the Aesthetic Use of RelabotulinumtoxinA to Treat Upper Face Wrinkles. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nFabi SG, et al. The potential role of biostimulators\/dermal fillers to address menopause-related skin conditions. Poster presented at IMCAS 2026; January 29-31, 2026; Paris, France.<\/li>\n<li>\nGalderma. Data on file. Menopause Patient Survey.<\/li>\n<li>\nWaibel J, et al. Bulk RNA-seq Analysis of Poly-L-Lactic Acid (PLLA-SCA) vs Calcium Hydroxyapatite (CaHA-R) Reveals a Novel, Adipocyte Mediated Regenerative Mechanism of Action Unique to PLLA. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.<\/li>\n<li>\nWaibel J, et al. Gene Analysis of Biostimulators: PLLA-SCA Triggers Regenerative Morphogenesis while CaHA-R Induces Inflammation upon Facial Injection. Poster presented at ASDS 2024 Annual Meeting; October 17-20, 2024; Orlando, Florida, United States.<\/li>\n<li>\nHuth S, et al. Molecular Insights into the effects of PLLA_SCA on Gene Expression and Collagen Synthesis in Human 3D Skin Models Containing Macrophages. <i>J Drugs Dermatol<\/i>. 2024;23(4):285\u2013288. doi: 10.36849\/JDD.7791.<\/li>\n<li>\nGalderma. Data on File. MA-46589.<\/li>\n<li>\nVleggaar D, et al. Consensus recommendations on the use of injectable poly-L-lactic-acid for facial and nonfacial volumization<i>. J Drugs Dermatol<\/i>. 2014;13(4 Suppl):s44\u2013s51.<\/li>\n<li>\nWidgegrow J, et al. A randomized, comparative study describing the gene signatures of poly-l-lactic acid (PLLA-SCA) and Calcium Hydroxyapatite (CaHA) in the treatment of nasolabial folds. Poster presented at IMCAS World Congress; February 1-3, 2024. Paris, France.<\/li>\n<li>\nDuracinsky M, et al. Safety of poly-L-lactic acid (New-Fill<sup>\u00ae<\/sup>) in the treatment of facial lipoatrophy: a large observational study among HIV-positive patients. <i>BMC Infect Dis<\/i>. 2014;14(474). doi: 10.1186\/1471-2334-14-474.<\/li>\n<li>\nZhang S and Duan E. Fighting against Skin Aging: The Way from Bench to Bedside. <i>Cell Transplant<\/i>. 2018;27(5):729\u2013738. doi: 10.1177\/0963689717725755.<\/li>\n<li>\nShuster S, et al. The influence of age and sex on skin thickness, skin collagen and density. <i>Br J Dermatol<\/i>. 1975;93(6):639-43. doi: 10.1111\/j.1365-2133.1975.tb05113.x.<\/li>\n<li>\nZarbafian M, et al. The emerging field of regenerative aesthetics\u2014where we are now. <i>Dermatol Surg<\/i>. 2022;48:101\u2013108. doi: 10.1097\/DSS.0000000000003239.<\/li>\n<li>\nFabi S, et al. 24-month clinical trial data on effectiveness and safety after correction of cheek wrinkles using a biostimulatory poly-L-lactic acid injectable implant. Poster presented at IMCAS World Congress; January 26-28, 2023; Paris, France.<\/li>\n<li>\nGoldberg D, et al. Single-arm study for the characterization of human tissue response to injectable poly-L-lactic acid. <i>Dermatol Surg.<\/i> 2013;39(6):915\u2013922. doi: 10.1111\/dsu.12164.<\/li>\n<li>\nDi Gregorio C, et al. 25+ years of experience with the Restylane portfolio of injectable HA fillers for facial aesthetic treatment. E-poster presented at AMWC; March 27-29, 2024; Monaco.<\/li>\n<li>\nNikolis A, et al. The role of clinical examination in midface volume correction using hyaluronic acid fillers: should patients be stratified by skin thickness? <i>Aesthet Surg J Open Forum<\/i>. 2020;2(1):1\u201312. doi: 10.1093\/asjof\/ojaa005.<\/li>\n<li>\nTalarico S, et al. High patient satisfaction of a HA filler producing enduring full-facial volume restoration: an 18- month open multicenter study.<i> Dermatol Surg. <\/i>2015;41:1361\u20131369. doi: 10.1097\/DSS.0000000000000549.<\/li>\n<li>\nRestylane. U.S. Instructions for use. Available <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.restylaneusa.com%2Fdocs%2FRestylane-IFU&amp;esheet=54401298&amp;newsitemid=20260121547346&amp;lan=en-US&amp;anchor=online&amp;index=5&amp;md5=e3742b789baa7a69dd46912b0535dcb7\" rel=\"nofollow\" shape=\"rect\">online<\/a>. Accessed January 2026.<\/li>\n<li>\nEdsman K, et al. Gel properties of hyaluronic acid dermal fillers. <i>Dermatol Surg<\/i>. 2012;38:1170\u20131179. doi: 10.1111\/j.1524-4725.2012.02472.x.<\/li>\n<li>\nGalderma. Data on file. MA-58650. Degree of modification of HA fillers.<\/li>\n<li>\nSeo K. Facial volumization with fillers. <i>Springer<\/i>. 2021;29\u201383. <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fdoi.org%2F10.1007%2F978-981-33-6212-3_2&amp;esheet=54401298&amp;newsitemid=20260121547346&amp;lan=en-US&amp;anchor=https%3A%2F%2Fdoi.org%2F10.1007%2F978-981-33-6212-3_2&amp;index=6&amp;md5=c20c26fba5385b5b63ee5807e82cd284\" rel=\"nofollow\" shape=\"rect\">https:\/\/doi.org\/10.1007\/978-981-33-6212-3_2<\/a>.<\/li>\n<li>\nKablik J, et al. Comparative physical properties of hyaluronic acid dermal fillers. <i>Dermatol Surg<\/i>. 2009:35S(1):302\u2013312. doi: 10.1111\/j.1524-4725.2008.01046.x.<\/li>\n<li>\nGalderma Data on file. MA-56724. X-strain and G\u2019 including Shaype.<\/li>\n<li>\nNikolis A, et al. Effectiveness and Safety of a New Hyaluronic Acid Injectable for Augmentation and Correction of Chin Retrusion. <i>J Drugs Dermatol<\/i>. 2024;23(4):255\u2013261. doi: 10.36849\/JDD.8145.<\/li>\n<li>\n\u00d6hrlund \u00c5 et al. Differentiation of NASHA and OBT Hyaluronic Acid Gels According to Strength, Flexibility, and Associated Clinical Significance <i>J Drugs Dermatol<\/i>. 2024;23(1):1332\u20131336. doi: 10.36849\/JDD.7648.<\/li>\n<li>\nBelmontesi M et al. Injectable Non-Animal Stabilized Hyaluronic Acid as a Skin Quality Booster: An Expert Panel Consensus <i>J Drugs Dermatol.<\/i> 2018;17(1):83\u201388.<\/li>\n<li>\nSolish N, et al. Dynamics of HA fillers formulated to maintain natural facial expression. <i>J Cosmet Dermatol.<\/i> 2019;18(3):738-746. doi: 10.1111\/jocd.12961.<\/li>\n<li>\nPhilipp\u2010Dormston WG, et al. Perceived naturalness of facial expression after HA filler injection in nasolabial folds and lower face. <i>J Cosmet Dermatol<\/i>. 2020;19(7):1600-1606. doi: 10.1111\/jocd.13205.<\/li>\n<li>\nAblon G, et al. Treatment of lateral canthal lines with RelabotulinumtoxinA, an investigational liquid botulinum toxin: clinical efficacy and safety results from the READY-2 phase 3 trial. <i>Toxicon<\/i>. 2024;237(1):107353. doi: 10.1026\/j.toxicon.2024.107353.<\/li>\n<li>\nRelfydess<sup>\u00ae<\/sup>. EU Summary of Product Characteristics.<\/li>\n<li>\nSundberg AL and Stahl U. Relabotulinum toxin &#8211; a novel, high purity BoNT-A1 in liquid formulation. Presented at TOXINS; January 16-17, 2021; virtual meeting.<\/li>\n<li>\nDo M, et al. Purification process of a complex-free highly purified botulinum neurotoxin type A1 (BoNT-A1) &#8211; relabotulinumtoxinA. Presented at TOXINS; July 27-30, 2022; Louisiana, United States.<\/li>\n<\/ol>\n<p>\n\u00a0<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>For further information:<\/b><\/p>\n<p>\nChristian Marcoux, M.Sc.<br \/>\n<br \/>Chief Communications Officer<br \/>\n<br \/><a target=\"_blank\" href=\"ma&#105;&#108;&#116;&#x6f;&#x3a;&#x63;&#x68;ri&#115;&#116;&#105;&#x61;&#x6e;&#x2e;&#x6d;ar&#99;&#111;&#117;&#x78;&#x40;&#x67;&#x61;ld&#101;&#114;&#109;&#x61;&#x2e;&#x63;&#x6f;m\" rel=\"nofollow\" shape=\"rect\">&#x63;&#x68;&#114;i&#x73;&#x74;&#105;&#97;n&#x2e;&#x6d;&#97;&#114;c&#x6f;&#x75;&#120;&#64;g&#x61;&#x6c;&#100;e&#x72;&#x6d;&#97;&#46;c&#x6f;&#x6d;<\/a><br \/>+41 76 315 26 50<\/p>\n<p>\nRichard Harbinson<br \/>\n<br \/>Corporate Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#x69;l&#116;&#x6f;:&#114;&#x69;&#x63;h&#97;&#x72;d&#46;&#x68;&#x61;r&#98;&#x69;n&#115;&#x6f;&#x6e;&#64;&#103;&#x61;l&#100;&#x65;&#x72;&#109;&#x61;&#x2e;c&#111;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x72;&#x69;&#x63;&#x68;&#x61;&#x72;&#x64;&#46;&#104;&#97;&#114;&#98;inso&#x6e;&#x40;&#x67;&#x61;&#x6c;&#x64;&#x65;&#x72;&#109;&#97;&#46;&#99;&#111;m<\/a><br \/>+41 76 210 60 62<\/p>\n<p>\nC\u00e9line Buguet<br \/>\n<br \/>Franchises and R&amp;D Communications Director<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#x61;&#x69;&#108;&#116;&#111;:c&#x65;&#x6c;&#x69;&#x6e;&#101;&#46;bu&#x67;&#x75;&#x65;&#x74;&#64;&#103;al&#x64;&#x65;&#x72;&#x6d;&#97;&#46;&#99;om\" rel=\"nofollow\" shape=\"rect\">&#x63;&#101;&#x6c;&#x69;&#110;&#x65;&#x2e;&#98;&#x75;&#x67;&#117;&#x65;&#x74;&#64;&#x67;&#x61;l&#x64;&#101;r&#x6d;&#97;&#46;&#x63;&#111;m<\/a><br \/>+41 76 249 90 87<\/p>\n<p>\nEmil Ivanov<br \/>\n<br \/>Head of Strategy, Investor Relations, and ESG<br \/>\n<br \/><a target=\"_blank\" href=\"mail&#116;&#111;&#58;&#101;&#109;&#x69;&#x6c;&#x2e;&#x69;&#x76;&#x61;&#x6e;ov&#64;g&#97;&#108;&#100;&#101;&#114;&#x6d;&#x61;&#x2e;&#x63;&#x6f;&#x6d;\" rel=\"nofollow\" shape=\"rect\">&#x65;m&#x69;&#108;&#x2e;&#105;v&#x61;n&#x6f;&#118;&#x40;&#103;a&#x6c;&#100;&#x65;&#114;m&#x61;&#46;&#x63;&#111;&#x6d;<\/a><br \/>+41 21 642 78 12<\/p>\n<p>\nJessica Cohen<br \/>\n<br \/>Investor Relations and Strategy Director<br \/>\n<br \/><a target=\"_blank\" href=\"mailto:jessica&#46;cohen&#64;gal&#100;&#101;&#114;&#109;&#97;&#46;&#99;&#111;&#109;\" rel=\"nofollow\" shape=\"rect\">jessica&#46;&#99;&#111;&#104;&#101;&#110;&#64;&#103;&#97;&#108;&#100;&#x65;&#x72;&#x6d;&#x61;&#x2e;&#x63;&#x6f;&#x6d;<\/a><br \/>+41 21 642 76 43<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>At IMCAS 2026, Galderma will present findings supporting Sculptra\u2019s\u00ae regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma\u2019s hyaluronic acid (HA) &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-62527","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"At IMCAS 2026, Galderma will present findings supporting Sculptra\u2019s\u00ae regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma\u2019s hyaluronic acid (HA) ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-22T06:06:04+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio\",\"datePublished\":\"2026-01-22T06:06:04+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/\"},\"wordCount\":2629,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260121547346\\\/en\\\/2698090\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/\",\"name\":\"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260121547346\\\/en\\\/2698090\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"datePublished\":\"2026-01-22T06:06:04+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260121547346\\\/en\\\/2698090\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20260121547346\\\/en\\\/2698090\\\/22\\\/GALDERMA_LOGO_BLACK_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/","og_locale":"en_US","og_type":"article","og_title":"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio - Pharma Trend","og_description":"At IMCAS 2026, Galderma will present findings supporting Sculptra\u2019s\u00ae regenerative properties and benefits on the body, including improving cellulite appearance, firmness, lift, projection, and contouring following its European Union (EU) Medical Device Regulation (MDR) certification, expanding its use to four body areas1-7 Multiple studies will reinforce the safety and efficacy of Galderma\u2019s hyaluronic acid (HA) ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/","og_site_name":"Pharma Trend","article_published_time":"2026-01-22T06:06:04+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio","datePublished":"2026-01-22T06:06:04+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/"},"wordCount":2629,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/","url":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/","name":"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","datePublished":"2026-01-22T06:06:04+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20260121547346\/en\/2698090\/22\/GALDERMA_LOGO_BLACK_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/imcas-2026-galderma-showcases-the-latest-scientific-advances-behind-the-industrys-broadest-injectable-aesthetics-portfolio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"IMCAS 2026: Galderma Showcases the Latest Scientific Advances Behind the Industry\u2019s Broadest Injectable Aesthetics Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62527","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=62527"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/62527\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=62527"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=62527"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=62527"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}